ADDITIONAL INDICATIONS

ENDOGENOUS NEUROSTEROIDS

GRX-917 could potentially benefit other neuropsychiatric and neurological disorders, beyond anxiety.

GRX-917 increases levels of endogenous neurosteroids, which:

1. Modulate GABA-A receptors, and
2. Inhibit NLRP3 inflammation.

Modulating GABA-A receptors could benefit neuropsychiatric indications, including various forms of anxiety and depression.

Inhibiting NLRP3 inflammation could benefit epilepsy, pain, obesity and several other neurological disorders.

Each of these indications have been validated for GRX-917 by either preclinical or clinical efficacy data.